Skip to main content
HOWL
NASDAQ Life Sciences

Werewolf Therapeutics Explores Strategic Alternatives, Including Potential Sale, Amidst Short Cash Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.86
Mkt Cap
$41.895M
52W Low
$0.53
52W High
$2.38
52W Position info
62% above low
Off High info
64% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

HOWL sits 62% above its 52-week low of $0.53.

Summary

Werewolf Therapeutics announced it is exploring strategic alternatives, including a potential sale or merger, while reporting Q4 and full-year 2025 financial results and projecting a cash runway into Q4 2026.


Key Events · Financing and Capital Events · HOWL

  • Exploration of Strategic Alternatives

    The company has initiated a process to explore a range of strategic alternatives to maximize stockholder value, including a potential sale, business combination, asset sale, or licensing arrangements. Piper Sandler & Co. has been engaged as the exclusive financial advisor.

  • Limited Cash Runway

    As of December 31, 2025, cash and cash equivalents were $57.1 million, projected to fund operations and capital requirements only into the fourth quarter of 2026. This short runway adds urgency to the strategic review process.

  • Fourth Quarter and Full Year 2025 Financial Results

    The company reported a net loss of $8.4 million for Q4 2025 and $60.8 million for the full year 2025. Research and development expenses decreased to $6.9 million in Q4 2025 from $15.7 million in Q4 2024, reflecting cost-cutting measures.


Analysis · HOWL · Life Sciences

Werewolf Therapeutics' announcement of exploring strategic alternatives, including a potential sale or merger, signals a critical juncture for the company. For a small biopharmaceutical firm with a cash runway projected only into the fourth quarter of 2026, this move suggests significant financial pressure and a need for a transformative solution. While it could lead to a beneficial acquisition, it also introduces substantial uncertainty regarding the company's future and its ability to continue as a standalone entity. Investors should monitor developments closely as the outcome will fundamentally impact shareholder value.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HOWL was trading at $0.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.9M. The 52-week trading range was $0.53 to $2.38. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HOWL - Latest Insights

HOWL
Nov 13, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.9836
Real-time Price: $1.04 info
Change: +$0.0564 (+6%) info
Market Cap: $51.029M info
HOWL
Nov 10, 2026, 4:37 PM EST
Filing Type: S-4/A
Importance Score:
8
Price at Filing: $0.970
Real-time Price: $1.04 info
Change: +$0.070 (+7%) info
Market Cap: $51.029M info
HOWL
Nov 09, 2026, 9:22 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.00
Real-time Price: $1.04 info
Change: +$0.040 (+4%) info
Market Cap: $51.029M info
HOWL
Oct 26, 2026, 5:23 PM EDT
Filing Type: S-4/A
Importance Score:
8
Price at Filing: $0.9806
Real-time Price: $1.04 info
Change: +$0.0594 (+6%) info
Market Cap: $51.029M info
HOWL
Sep 22, 2026, 5:04 PM EDT
Filing Type: S-4
Importance Score:
9
Price at Filing: $0.9707
Real-time Price: $1.04 info
Change: +$0.0693 (+7%) info
Market Cap: $51.029M info